Latest news

• WHO publishes first-ever fungal priority pathogens list in face of antimicrobial resistance

  The list highlights the public health threat presented by fungal infections on a global scale. ... It was noted that during the COVID-19 pandemic, reported incidences of invasive fungal infections increased considerably among hospitalised patients.

• EMA accepts Mundipharma’s application for invasive candidiasis treatment rezafungin

  Rezafungin is a next-generation, once-weekly echinocandin currently in development for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia. ... Brian Sheehan, chief scientific officer at Mundipharma,

• Shionogi and F2G partner to develop antifungal treatment olorofim

  Shionogi and F2G have partnered to develop and commercialise the new antifungal agent olorofim – formerly F901318 – for invasive fungal infections in Europe and Asia. ... Olorofim is currently in a phase 2b open-label study, focusing on rare and

• Pfizer acquires Amplyx Pharmaceuticals, including new potential class of therapeutics

  Pfizer said that fosmanogepix offers a new potential class of therapeutics for the treatment of fungal infections that have become resistant of typical antifungal medications. ... to-treat bacterial, viral and fungal infections,” said Angela Lukin,

• UK biotech bags €1.5m grant for new antibiotic class

  abdominal infections (cIAI), focusing on a group of problem pathogens known collectively as ESKAPE – Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.